Most recently, NICE has published guidance on the use of liraglutide (Victoza®, Novo Nordisk, Bagsværd, Denmark), a GLP-1 analogue, which was approved by the European Medicines Agency in 2009 for use by people with T2DM. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.